Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Nov;10(11):2768-2780.
doi: 10.1038/s41564-025-02067-8. Epub 2025 Jul 25.

Desmocollin 2 is a dominant entry receptor for Epstein-Barr virus infection of epithelial cells

Affiliations

Desmocollin 2 is a dominant entry receptor for Epstein-Barr virus infection of epithelial cells

Hua Zhang et al. Nat Microbiol. 2025 Nov.

Abstract

Epstein-Barr virus (EBV) can infect B cells and epithelial cells, and cause lymphomas and various epithelial malignancies. During epithelial cell infection, EBV employs a complex combination of viral glycoproteins and host receptors. However, the exact mechanism and whether a dominant receptor exists remain unclear. Here we identify desmocollin 2 (DSC2) as a dominant EBV entry receptor for epithelial cell infection using CRISPR-Cas9 screening. Knockout of DSC2 reduced EBV infection in both nasopharyngeal and gastric epithelial cell lines, and infection was rescued when DSC2 expression was restored. Expression of human DSC2 in non-EBV-susceptible hamster cell lines enabled susceptibility to EBV. Furthermore, we found that DSC2 directly binds to EBV glycoprotein H/glycoprotein L through its extracellular domain, particularly the preEC-EC2 regions, which could be targeted by polyclonal antibodies, therefore blocking EBV infection in primary epithelial cells. DSC2 enabled virus entry independent of Ephrin receptor A2. These findings could aid development of currently unavailable animal models and support development of targeted therapies.

PubMed Disclaimer

Conflict of interest statement

Competing interests: The authors declare no competing interests.

References

    1. Damania, B., Kenney, S. C. & Raab-Traub, N. Epstein–Barr virus: biology and clinical disease. Cell 185, 3652–3670 (2022). - DOI - PubMed - PMC
    1. Young, L. S., Yap, L. F. & Murray, P. G. Epstein–Barr virus: more than 50 years old and still providing surprises. Nat. Rev. Cancer 16, 789–802 (2016). - DOI - PubMed
    1. Farrell, P. J. Epstein–Barr virus and cancer. Annu. Rev. Pathol. 14, 29–53 (2019). - DOI - PubMed
    1. Zhong, L. Y. et al. Research landmarks on the 60th anniversary of Epstein–Barr virus. Sci. China Life Sci. 68, 354–380 (2025). - DOI - PubMed
    1. Hutt-Fletcher, L. M. EBV glycoproteins: where are we now? Future Virol. 10, 1155–1162 (2015). - DOI - PubMed - PMC

MeSH terms

LinkOut - more resources